These results confirmed that in vitro dihydrolycorine treatment could prevent MI-induced myocardial fibrosis and cardiomyocyte hypertrophy and may thus mediate Runx1 to exert a cardioprotective effect. Here, RUNX1 is linked to Myocardial fibrosis.